Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
The top 600 biopharma firms added $487 billion in market capitalisation in 2020, according to the Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review report,…
Inova and the Biotechnology Innovation Organization (BIO), in partnership with Evaluate announce the second annual series of Virtual Partnering events focused on critical…
COVID-19 will continue to be a defining issue for pharma and biotech companies in 2021, but overall the sector will start the year from a position of strength, according…
Vantage releases its half-year analysis of sector performance: Pharma, Biotech and Medtech Half-Year Review 2018
Eleventh annual EvaluatePharma World Preview 2018, Outlook to 2024 report launches at BIO 2018.
Annual “EvaluatePharma Orphan Drug 2018 Report” sees Orphan drugs capture a fifth of worldwide prescription sales by 2024 as sales grow to $262bn.
EP Vantage releases its annual analysis of sector performance: Pharma, Biotech and Medtech 2017 in Review.
EP Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2018.
EvaluateMedTech Report Launches in Conjunction with The MedTech Conference.
EP Vantage Releases Half-Year Reviews of Pharma & Biotech and Medtech Performance.
Latest growth forecasts show optimism surrounding new therapies coming to market counterbalanced by more stringent pricing policy enforcement.
New Case Studies Highlight Niche Patient Population Identification and Analysis for Enhanced Portfolio Decision-making Using Evaluate’s Epi Analyzer